Even with an effective vaccine, an estimated 240 million people are chronically infected with hepatitis B virus （HBV） worldwide. Current antiviral therapies, including interferon and nucleot（s）ide analogues, rarel...Even with an effective vaccine, an estimated 240 million people are chronically infected with hepatitis B virus （HBV） worldwide. Current antiviral therapies, including interferon and nucleot（s）ide analogues, rarely cure chronic hepatitis B. Animal models are very crucial for understanding the pathogenesis of chronic hepatitis B and developing new therapeutic drugs or strategies. HBV can only infect humans and chimpanzees, with the use of chimpanzees in HBV research strongly restricted. Thus, most advances in HBV research have been gained using mouse models with HBV replication or infection or models with HBV-related hepadnaviral infection. This review summarizes the animal models currently available for the study of HBV infection.展开更多
Objective: To assess the efficacy of Yanggan Aoping Mixture (养肝澳平, YGAPM) in treatinghepatitis B. Methods: Patients suffered from chronic hepatitis B were treated with YGAPM. Observe theirshort-- and long--term ef...Objective: To assess the efficacy of Yanggan Aoping Mixture (养肝澳平, YGAPM) in treatinghepatitis B. Methods: Patients suffered from chronic hepatitis B were treated with YGAPM. Observe theirshort-- and long--term efficacy and the change of serum hepatitis B virus marker. In experiment, the effects ofYGAPM in treating rat's liver injury as well as HBV--infected tree shrew and duck HBV--infected ducks were observed. Results: In 79 cases of chronic persistent hepatitis, the markedly effective rate was 60. 76%, and further raised to 70. 00 % in follow-up study in 40 cases. In 73 cases of chronic active hepatitis, the markedly effective rate was 60. 27%, and further raised to 62. 50% in 32 follow-up cases. In the treatment group, 85 of the119 cases (71. 43 % ) with HBeAg-positive were converted to negative. Whereas in the control group, only 40 of89 HBeAg-positive cases (44. 94 % ) were converted to negative, P < 0. 01. Results of experimental studyshowed that negative conversion rate of tree shrew infected with HBV marker was raised, while the duck HBVDNA in infected duck blood was inhibited. Those compared with the control group separately, the differencewas markedly significant. Conclusion: YGAPM is an effective drug in treating chronic hepatitis B, and it couldeffectively convert the marker to negative.展开更多
基金supported by the Chinese National Key Technology R&D Program(2015BAI09B06)the National Science and Technology Major Project for Infectious Diseases of China(2012ZX10004503,2017ZX10304402-002-005)the National Natural Science Foundation of China(81461130019)
文摘Even with an effective vaccine, an estimated 240 million people are chronically infected with hepatitis B virus （HBV） worldwide. Current antiviral therapies, including interferon and nucleot（s）ide analogues, rarely cure chronic hepatitis B. Animal models are very crucial for understanding the pathogenesis of chronic hepatitis B and developing new therapeutic drugs or strategies. HBV can only infect humans and chimpanzees, with the use of chimpanzees in HBV research strongly restricted. Thus, most advances in HBV research have been gained using mouse models with HBV replication or infection or models with HBV-related hepadnaviral infection. This review summarizes the animal models currently available for the study of HBV infection.
文摘Objective: To assess the efficacy of Yanggan Aoping Mixture (养肝澳平, YGAPM) in treatinghepatitis B. Methods: Patients suffered from chronic hepatitis B were treated with YGAPM. Observe theirshort-- and long--term efficacy and the change of serum hepatitis B virus marker. In experiment, the effects ofYGAPM in treating rat's liver injury as well as HBV--infected tree shrew and duck HBV--infected ducks were observed. Results: In 79 cases of chronic persistent hepatitis, the markedly effective rate was 60. 76%, and further raised to 70. 00 % in follow-up study in 40 cases. In 73 cases of chronic active hepatitis, the markedly effective rate was 60. 27%, and further raised to 62. 50% in 32 follow-up cases. In the treatment group, 85 of the119 cases (71. 43 % ) with HBeAg-positive were converted to negative. Whereas in the control group, only 40 of89 HBeAg-positive cases (44. 94 % ) were converted to negative, P < 0. 01. Results of experimental studyshowed that negative conversion rate of tree shrew infected with HBV marker was raised, while the duck HBVDNA in infected duck blood was inhibited. Those compared with the control group separately, the differencewas markedly significant. Conclusion: YGAPM is an effective drug in treating chronic hepatitis B, and it couldeffectively convert the marker to negative.
